Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience

(2016) M.-C. Tsai et al.   CLINICAL MICROBIOLOGY AND INFECTION

Hepatitis B virus: new therapeutic perspectives

(2016) Chih-Lin Lin et al.   LIVER INTERNATIONAL

AASLD guidelines for treatment of chronic hepatitis B

(2015) Norah A. Terrault et al.   HEPATOLOGY

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

(2015) Kosh Agarwal et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

(2014) Rujuta A Bam et al.   ANTIVIRAL THERAPY

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis

(2013) Grace Lai-Hung Wong et al.   HEPATOLOGY

Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus–Related Cirrhosis

(2012) Seyfettin Köklü et al.   Clinical Gastroenterology and Hepatology

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

(2010) Yun-Fan Liaw et al.   HEPATOLOGY

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis

(2009) Ju Hyun Shim et al.   JOURNAL OF HEPATOLOGY

Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors

(2007) Giovanna Fattovich et al.   JOURNAL OF HEPATOLOGY